Ab#0596 #ACR23 @RheumNow R Furie on Decravacitinib in SLE 48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv